Host:

E.coli

Tag:

His-tag

AA Sequence:

CTGCAGGATCCGTGTAGCAATTGCCCGGCAGGTACCTTCTGTGATAATAATCGCAATCAGATCTGTAGCCCGTGTCCGCCGAATAGCTTCAGTAGCGCCGGCGGTCAGCGCACCTGTGATATCTGTCGCCAGTGTAAAGGCGTGTTCCGTACCCGTAAAGAATGCAGCAGCACCAGTAATGCCGAATGTGATTGTACCCCGGGCTTCCATTGCCTGGGCGCAGGTTGTAGCATGTGTGAACAGGATTGCAAACAGGGTCAGGAACTGACCAAAAAAGGCTGTAAAGATTGCTGCTTCGGTACCTTCAATGATCAGAAACGCGGTATCTGTCGTCCGTGGACCAATTGCAGCCTGGATGGCAAAAGTGTTCTGGTTAATGGTACCAAAGAACGTGATGTTGTGTGCGGTCCGAGTCCGGCAGATCTGAGCCCGGGCGCAAGCAGTGTGACCCCGCCTGCTCCGGCACGTGAACCGGGTCATAGTCCGCAG

Expression vector:

pet-22b(+)

Soluble:

PBS, 4M Urea, PH7.4

BiowMW:

~24kDa

Purification & Purity:

Transferred into competent cells and the supernatant was purified by NI column affinity chromatography and the purity is > 85% (by SDS-PAGE).

Storage & Stability:

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Background:

TNFRSF9 is a member of the tumor necrosis factor receptor superfamily. It is also called 4-1BB or CD137. 4-1BB/CD137/TNFRSF9 is expressed in activated CD4+ and CD8+ T cells, natural killer cells and dendritic cells. The ligand 4-1BBL/CD137L/TNFSF9 on antigen presenting cells binds to 4-1BB/CD137/TNFRSF9 and costimulates the activation of T cells. The binding of agonistic antibodies to 4-1BB/CD137/TNFRSF9 also leads to costimulation for T cell activation. Studies have shown the effectiveness of targeting 4-1BB/CD137/TNFRSF9 by its agonistic antibodies in cancer immunotherapy.

Note:

For research use only, not for use in diagnostic procedure.